Answers are grounded in this paper and cite their sources.
The widespread use of antibiotics can disrupt intestinal microbial homeostasis, resulting in complications ranging from mild diarrhoea to life-threatening Clostridium difficile infection. While probiotic supplementation serves as a standard clinical therapy to counteract these effects, its efficacy is severely undermined by reduced bioactivity due to residual antibiotics in the gut. Current strategies to engineer antibiotic-resistant probiotics, through physical encapsulation or genetic editing, have shown some promise, but they either sacrifice metabolic activity or risk the dissemination of antibiotic resistance genes. To break this impasse, we drew inspiration from natural superbugs and created drug-resistant probiotics through the chemical fortification with artificial β-lactamases. This breakthrough stemmed from the discovery that Calgary Framework-20 (CALF-20) exhibits effective catalytic activity in hydrolyzing β-lactam antibiotics, even under physiological environments. Theoretical and experimental analyses unraveled that this robust activity originates from the synergistic activation of water molecules by its organic ligands and metal ions. Capitalizing on this mechanism, we engineered a drug-resistant probiotic (LGG@CALF-20-B) by decorating the model probiotic Lactobacillus rhamnosus GG (LGG) with CALF-20 nanoparticles. Strikingly, in vitro proliferation assays demonstrated that the fortified LGG@CALF-20-B group achieved a staggering 10 4 to10 5 -fold higher cell density compared to the single LGG group in an antibiotics-containing environment. In vivo experiments further demonstrated that LGG@CALF-20-B administration robustly restored microbial homeostasis to a level comparable with that of healthy controls in mice and Beagles subjected to β-lactam antibiotics. Thus, beyond introducing a potent artificial enzyme, this study pioneers a versatile and safe platform for constructing drug-resistant probiotics, thereby heralding a new frontier for next-generation bio-therapeutics.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: